Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Bioactive Compounds

Volume 7 Issue 1
ISSN: 1573-4072
eISSN: 1875-6646


   All Titles

  CRLX101 (formerly IT-101) A Novel Nanopharmaceutical of Camptothecin in Clinical Development
  pp.8-14 (7) Authors: Cissy Young, Thomas Schluep, Jungyeon Hwang, Scott Eliasof

CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CDPEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale drug carrier system, the cyclodextrin polymeric nanoparticle technology, referred to as “CDP”, has unique design features and capabilities. Specifically, CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological properties that enhance CPT pharmacodynamics and efficacy.

  Keywords: Nanopharmaceutical, oncology, camptothecin, topoisomerase 1
  Affiliation: Senior Director, Research, Cerulean Pharma Inc. Cambridge MA, USA.
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers


  Copyright © 1994 - 2015   Bentham Science Publishers